TORONTO, ONTARIO -- (Marketwired) -- 05/07/13 -- Biologix Hair Inc. (OTCBB: BLGX) (OTCQB: BLGX) has appointed Alan J. Bauman, MD to its Medical Advisory Board, where he will serve with Dr. Edward A.M. Ball, Dr. Arthur G. Handal and Dr. Craig Ziering, Medical Advisory Board Chairman.
Dr. Alan J. Bauman received his Doctor of Medicine degree with Cor Et Manus award from New York Medical College in Valhalla, NY and received surgical residency training at Beth Israel Medical Center and Mt. Sinai Medical Center in New York before training in hair transplant surgery. In 1997 he founded Bauman Medical Group in Boca Raton, Florida, his private practice exclusively dedicated to the treatment of hair loss in men and women.
An internationally renowned hair loss expert, Dr. Bauman is one of only approximately one hundred hair restoration physicians to receive certification by the esteemed American and International Board of Hair Restoration Surgery and one of only fifty physicians recommended by the American Hair Loss Association worldwide. He has built an international practice which has treated over 15,000 hair loss patients and has been extensively featured in the world's leading media in print, radio and television as a successful early-adopter of the most advanced technologies in the diagnosis and treatment of hair loss.
Dr. Bauman has authored several textbook chapters on Eyelash Transplant surgery, and is widely known for pioneering minimally-invasive hair transplant surgery as the first ABHRS-certified surgeon to routinely use NeoGraft for no-scalpel/no-stitch, no-linear-scar Follicular Unit Extraction procedures. Dr. Bauman has also been at the forefront of Low Level Laser Therapy for hair growth, topical prostaglandin analogs, Platelet Rich Plasma (PRP), Body Hair Transplantation (BHT), genetic hair loss testing, pharmacy compounded Formula 82M minoxidil, Cross-Sectional Hair Bundle Trichometry using HairCheck and Social Media. He has also been a passionate supporter and participating surgeon in Operation Restore, the pro bono hair restoration program of the International Society of Hair Restoration Surgery.
A frequent faculty member and lecturer at international medical conferences and Live Surgery Workshops, Dr. Bauman serves on medical advisory boards for several Fortune 500 companies, such as Merck, Procter & Gamble and others. His Consulting Division performs scientific research and other services for companies entering or expanding into the hair restoration sector. Current projects include the design and completion of the clinical trial of Pantene's AgeDefy Hair Thickening Treatment and scientific presentations at the global product launch events in Beijing, New York, Sao Paulo and Edinburgh.
Dr. Alan Bauman is an active member of the International Society of Hair Restoration Surgery, American Academy of Anti-Aging Medicine, American Hair Loss Council, International Alliance of Hair Restoration Surgeons and the American Society of Hair Restoration Surgery. Dr. Bauman is also a Palm Beach County Medical Society member and a recent delegate to the Florida Medical Association's Annual Meeting. A prominent philanthropic business leader in the community, Dr. Bauman is proud of the fact that he was the first-ever physician recipient of the prestigious Greater Boca Raton Chamber of Commerce's Business Leader of the Year Award in the history of the honor.
Dr. Alan Bauman is proud to be a founding board member of the award-winning Musical Cares charity, a 501(c)3 non-profit organization which donates musical instruments to economically-strapped school music programs around the U.S., enabling less fortunate children to enjoy the gift of music. Dr. Bauman lives with his wife of fifteen years, Karen, and their two sons in Boca Raton, FL. In their spare time, they enjoy the active outdoor lifestyle, arts and culture of South Florida and supporting the local community through volunteer work and numerous charitable organizations.
Dr. Alan Bauman is optimistic about the progress that Biologix has made so far in South America and is excited about being involved with bringing this new treatment option to the U.S. and beyond. "Hair loss can be a devastating condition for many of the hundreds of millions of men and women worldwide. New technology and treatments bring hope to those who are suffering, giving hair loss patients new options and allow caring, passionate physicians to really make a difference in their patients' lives."
Ron Holland, Biologix Chairman and CEO, stated, "We appreciate Dr. Bauman's eagerness to assist with the growth of Biologix Hair Inc. through participating on the Company's Medical Advisory Board and look forward to his input."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.
Biologix Hair Inc.
Toll Free: 1 855.292.8585 or 647.494.8001
Most Popular Stories
- Small Businesses Add 3 More Worries to Their List
- 2015 Mazda MX-5 Miata Is Fast and Eager
- Tablets, Cars Drive AT&T Gains
- DOMA Tech Adding Jobs to Process VA Claims
- Tech Firms Flock to LA's 'Silicon Beach'
- Apple Warns of China iCloud Attack
- Job Hunting Is Hard Work
- Consumer Prices Edge Up, Surprising Economists
- Ford, GM Expect to Report Strong Profits
- Stocks Subdued After Gains Earlier in Week